GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...
Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...
The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. | ...
As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own ...
Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small ...
AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups. | AstraZeneca’s oral relaxin ...
AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis ...
Studying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists ...
BioXcel Therapeutics has filed for bankruptcy and lined up a deal for T | BioXcel Therapeutics has filed for bankruptcy and ...
Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the ...
Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 ...
A new report on the health of the Massachusetts biotech scene has painted a mixed picture of how drug developers are faring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results